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doi:10.1016/j.ejvs.2009.11.022Abstract Objective: This study aims to assess the predictive value of residual venous
obstruction (RVO) for recurrent venous thrombo-embolism (VTE) in a study using D-dimer to
predict outcome.
Design: This is a multicentre randomised open-label study.
Methods: Patients with a first episode of idiopathic VTE were enrolled on the day of anticoa-
gulation discontinuation when RVO was determined by compression ultrasonography in those
with proximal deep vein thrombosis (DVT) of the lower limbs. D-dimer was measured after 1
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Risk Factors for Recurrent Venous Thromboembolism 357abnormal D-dimer were randomised to resume anticoagulation or not. The primary outcome
measure was recurrent VTE over an 18-month follow-up.
Results: A total of 490 DVT patients were analysed (after excluding 19 for different reasons
and 118 for isolated pulmonary embolism (PE)). Recurrent DVT occurred in 19% (19/99) of
patients with abnormal D-dimer who did not resume anticoagulation and 10% (31/310) in
subjects with normal D-dimer (adjusted hazard ratio: 2.1; p Z 0.02). Recurrences were similar
in subjects either with (11%, 17/151) or without RVO (13%, 32/246). Recurrent DVT rates were
also similar for normal D-dimer, with or without RVO, and for abnormal D-dimer, with or
without RVO.
Conclusions: Elevated D-dimer at 1 month after anticoagulation withdrawal is a risk factor for
recurrence, while RVO at the time of anticoagulation withdrawal is not.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.The optimal duration of treatment with vitamin K antago-
nists (VKAs) after a first episode of unprovoked venous
thromboembolism (VTE) is still uncertain.1e3 The latest
edition of the American College of Chest Physicians’
guidelines recommends that patients with unprovoked VTE
receive at least 3 months of anticoagulation. Later,
patients should be evaluated for the risk-benefit ratio of
long-term therapy.4 Long-term treatment is recommended
in those in whom risk factors for bleeding are absent and for
whom good anticoagulant monitoring is achievable. This
recommendation attaches a relatively high value to the
prevention of recurrent VTE and a lower value to the
burden of long-term therapy. However, the risk of recur-
rence gradually decreases in the first 6e12 months after
the initial episode.5 As a result, the benefits of extending
anticoagulation should be balanced against the risk of
bleeding.1e4,6,7
Several factors such as D-dimer, thrombophilia and
residual venous obstruction (RVO) have been evaluated for
their predictive value for recurrence of VTE. In previous
reports,8e10 post-anticoagulation D-dimer levels were
shown to have a high negative predictive value for recur-
rent VTE. So far only one randomised trial, the PROLONG
study, has been performed to establish the role of D-dimer
for assessing the risk of recurrence after a first episode of
VTE.11 The PROLONG study showed that, in patients treated
with VKAs for at least 3 months for a first episode of idio-
pathic VTE, an abnormal D-dimer at 1 month after anti-
coagulation suspension was associated with a statistically
significant higher risk for recurrence when compared with
normal D-dimer and prolonging anticoagulation significantly
reduced the risk of recurrent VTE in patients with abnormal
D-dimer.11
Two prospective studies in single centres have shown
that markers of hypercoagulability, such as D-dimer and
prothrombin fragment F1þ2, but not RVO, are risk
factors for recurrent VTE after anticoagulation suspen-
sion.12,13 However, more recently, the AESOPUS14 and
DACUS15 randomised studies indicated that the duration
of anticoagulation could be guided by ultrasound find-
ings as patients with recanalised veins had a lower risk
of recurrence when compared with subjects with RVO.
It is unknown whether RVO, alone and in combination
with D-dimer, could also be a predictor of cardiovas-
cular events and occult cancer in subjects with a first
episode of idiopathic proximal deep vein thrombosis
(DVT).The aim of the present study was to assess the predictive
value of RVO and D-dimer, alone and in combination, for
recurrent VTE, cardiovascular events and cancer after
anticoagulation withdrawal for a first episode of DVT of the
lower limbs in subjects enrolled in the randomised multi-
centre PROLONG study.
Methods
Study patients
As reported previously,11 the PROLONG study was a mul-
ticentre randomised open-label clinical trial in patients
aged 18e85 years with a first episode of objectively
documented symptomatic idiopathic VTE, either proximal
lower extremity DVT and/or pulmonary embolism (PE). In
this post hoc analysis, results are reported only in the
subgroup of patients with proximal DVT with or without
PE. Patients were eligible after receiving at least 3 months
of VKA therapy (either warfarin (Coumadin, Bristol Myers
Squibb) or acenocoumarol (Sintrom, Novartis Pharma))
with a target International normalised ratio (INR) of 2.5
(range 2.0e3.0).
Idiopathic or unprovoked VTE was defined as an episode
not associated with pregnancy or puerperium, recent (i.e.,
within 3 months) fracture or plaster casting of a leg, immo-
bilisation with confinement to bed for 3 or more consecutive
days, surgery under general anaesthesia lasting 30 min,
active malignancy, antiphospholipid antibody syndrome or
antithrombin deficiency. Exclusion criteria were serious liver
disease, renal insufficiency (plasma creatinine >2 mg dl1),
other indications for anticoagulation or contraindications for
such treatment, limited life expectancy or geographical
inaccessibility. The institutional Ethics Committees of all
participating clinical centres approved the study. Written
informed consent was obtained by all enrolled patients.
Study procedures
Study procedureswere previously described.11 Briefly, at the
end of the intended anticoagulation period, subjects were
assessed for eligibility. Patients also underwent compression
ultrasonography (CUS) of the proximal deep veins in both legs
to measure the diameter of any residual thrombus in the
common femoral, superficial femoral and popliteal veins
according to the method of Prandoni et al.16 In an effort to
ELIGIBLE PATIENTS  
N = 627 
Enrolment visit and VKAs interrupted 
3 pt withdrew consent  
         5 pt excluded (4 for DVT , 1 for SVT) 
after 30±10 days 
D-dimer testing   
N = 619 
Abnormal                               Normal 
N= 226 (36.5%)       N= 393   
Excluded for LAC or AT 
deficiency  
N=4 N=7
N=222        N= 386 
   randomisation      VKAs stopped 
VKAs resumed      VKAs not resumed  
 N=101    N=121  N=386 
Proximal DVT  
without   N=73    N=66  N=242 
or with PE   N=26    N=15  N=68 
Total    N= 81    N= 99  N=310 
Excluded for isolated PE N=20                      isolated PE N=22     isolated PE N= 76 
(5 pt. refused VKAs) 
 Follow-Up:   18 months 
VKAs = Vitamin K antagonists 
DVT = deep vein thrombosis 
SVT = superficial vein thrombosis 
PE = pulmonary embolism 
Figure 1 Prolong study flow-chart.
358 B. Cosmi et al.standardise the measurement of RVO across 30 centres,
a video of a practical session showing the measurement of
RVO was sent to all the participating centres.
Anticoagulation was stopped on the same day and the
next visit was scheduled after 30  10 days. Patients with
recurrent events between discontinuation of VKA therapy
and the follow-up visit were excluded from further
analysis.At the 30-day visit, venous blood samples were taken for
D-dimer and thrombophilia tests. D-dimer was assessed
using the Clearview Simplify D-dimer assay (Inverness
Medical Professional Diagnostics, Bedford, UK and Louis-
ville, CO, USA; kindly provided by the Instrumentation
Laboratory company, Milan, Italy). This is a qualitative,
fast, whole blood method, previously shown to perform
well in VTE diagnosis.17 Patients with a normal D-dimer test
Table 1 Base-line characteristics of the 490 patients with proximal DVT with or without PE.
Normal-Dd
(n Z 310)a
All patients with
abnormal-Dd
(n Z 180)
pc Abnormal-Dd
No VKA
(n Z 99)b
Abnormal-
Dd
þ VKA
(n Z 81)
pc RVO absent
(n Z 300)a
RVO present
(n Z 178)b
pc
Female sex n (%) 129 (41.6) 91 (50.5) 0.07 54 (54.5) 37 (45.6) 0.30 140 (46.6) 75 (42.1) 0.75
Age
Mean(95%CI) yr 46.9 (4.2) 70.7 (1.25) <0.001d 67.8 (0.89) 79.6 (0.86) 0.26d 62.7 (2.8) 63.2 (2.2) 0.75d
65 yr n (%) 133 (42) 132 (73) <0.0001 71 (72) 61 (75) 0.7 157 (52) 101 (57) 0.70
Type of venous thromboembolism n (%)
Proximal DVT (no PE) 242 (78) 139 (77) 0.91 73 (81) 66 (81) 0.29 223 (74) 150 (84) 0.015
DVT þ symptomatic PE 68 (22) 41 (13) 0.91 26 (20) 15 (19) 0.29 77 (26) 28 (16) <0.001
Residual venous obstruction (%) 111 (37) 67 (38) 0.82 40 (42) 27 (33) 0.4 Abnormal-DD Abnormal-DD
110 (37) 67 (38) 0.90
Congenital thrombophilic alteration/s n (%) Examined Examined Examined Examined Examined Examined
291 174 97 77 281 173
60 (21) 42 (24) 0.35 19 (20) 23 (30) 0.20 64 (23) 35 (20) 0.74
Duration of previous anticoagulant
treatment n (%)
6 months e n (%) 65 (21) 29 (16) 0.2 13 (13) 16 (20) 0.31 59 (20) 33 (19) 0.85
7e12 months e n (%) 149 (48) 106 (59) 0.02 61 (67) 45(56) 0.50 151 (50) 99 (56) 0.30
>12 months e n (%) 96 (31) 45 (25) 0.19 25 (25) 20 (25) 0.93 90 (30) 46 (26) 0.38
Time elapsed between enrolment and
assignment to the groups
Mean  SD days 31 SD 9.6 33 SD 7.0 0.15d 33 SD 6.4 33 SD 7.6 0.81d 32 SD 8.3 31 SD 6.4 0.85d
Total duration of follow-up yr 566 314 162 152 535 331
Follow-up Mean (95% CI) yr 1.8 (0.1) 1.8 (0.1) 1.6 (0.2) 1.9 (0.2) 1.8 (0.1) 1.9 (0.1)
Dd denotes D-dimer; VKA Z vitamin K antagonist treatment; DVT Z deep vein thrombosis; PE Z pulmonary embolism.
a In 9 subjects CUS was not available.
b In 3 subjects CUS was not available.
c P value refers to chi-squared test unless specified.
d t-test.
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Table 2A Main outcomes by treatment assignment (intention-to-treat analysis).
Outcomes Normal-Dd Abnormal-Dd No VKA Abnormal-Dd þ VKA
n. 310 n. 99 n. 81
n/n Total (%) 31/310 (10) 19/99 (19) 4/81 (4.9)
n/100 Person-Yr (%) 31/566 (5.5) 19/162 (12) 4/152 (2.6)
Type of recurrent VTEa
DVT 28 16 1
DVT þ PE 3 3 0
Isolated PE 0 0 1
Major bleeding episode 0 0 2
VKA denotes vitamin K antagonist treatment; Dd Z D-dimer; VTE Z venous thromboembolism; DVT Z deep vein thrombosis;
PE Z pulmonary embolism.
a 27 DVTs occurred in the contralateral and 23 in the ipsilateral leg; 1 event was DVT of the upper limb.
360 B. Cosmi et al.did not resume VKAs, whereas those with an abnormal D-
dimer result were randomly assigned to either resume or
not resume VKAs (INR range 2.0e3.0) during the subsequent
follow-up period of up to 18 months. A different random-
isation sequence for each study site, using blocks of 10, was
computer-generated and encapsulated in a randomisation
computer program.
Thrombophilia testing was performed as previously repor-
ted.11 Patients diagnosed with antiphospholipid syndrome or
antithrombin deficiency resumed anticoagulation and were
excluded from further analysis.Table 2B Main outcomes according to the absence or
presence of RVO.
Outcomes RVO absenta RVO presenta
N Z 246 (no VKA)b N Z 151 (no VKA)c
n/n total (%) 32/246 (13) 17/151 (11.2)
n/100 person-Yr (%) 32/535 (6.0) 17/331 (5.1)
Type of recurrent VTE
DVT 28 15
DVT þ PE 4 2
Isolated PE 0 0
VKA denotes vitamin K antagonist treatment; RVO Z residual
venous obstruction; VTE Z venous thromboembolism;
DVT Z deep vein thrombosis; PE Z pulmonary embolism.
a CUS was not available in 12 subjects (of whom 1 had
a recurrent event).
b 1 Recurrence was observed in the group of subjects without
RVO (n.55) who resumed VKA (1.8%).
c 1 Recurrence and 2 bleeding events were observed in the
group of subjects with RVO (n.27) who resumed VKA (11.1%).Follow-up and study outcomes
Study enrolment started in September 2002 and ended on
31 January 2005. After enrolment, patients were seen at
each clinical centre at 3- to 6-month intervals. The primary
outcome was the composite of confirmed recurrent VTE and
major bleeding events. Patients were instructed to refer to
the clinical centre immediately if they developed symp-
toms suggestive of VTE or bleeding.
In cases of suspected recurrent DVT, the results of CUS
were compared with those of the last available previous
examination. A recurrent DVT was diagnosed if a previously
fully compressible segment (contralateral or ipsilateral) was
no longer compressible or if an increase of at least 4 mm in
the diameter of the residual thrombus during compression
was detected.18 When thrombus diameter changed between
1.1 mm and 3.9 mm, or in cases of high/moderate clinical
probability and normal CUS, the examination was repeated
5e7 days later. In patients with suspected PE, the diagnosis
of recurrence was based on objective algorithms11 using
clinical probability, ventilationeperfusion lung scanning or
helical computed tomography, compression ultrasonography
and/or D-dimer, if indicated.
Bleeding events were defined as major if retroperitoneal
or intracranial, or associated with a decrease in the hae-
moglobin of 2.0 g dl1, or if they required transfusion of
2 units of blood, or if surgery or invasive procedures were
necessary to stop bleeding.6
During follow-up, cardiovascular events such as acute
coronary syndromes, stroke, transient ischaemic attacks
and peripheral acute thrombosis were recorded. Events
were diagnosed on the basis of hospital discharge letters,according to the international and national guideline diag-
nostic criteria.19,20 Death was considered of cardiovascular
origin in the absence of other known causes (e.g., cancer).
Newly diagnosed cancers were also recorded with infor-
mation taken from hospital discharge letters or oncological
evaluation. All suspected outcome events, deaths, hospital
discharge letters and clinical investigation results were
evaluated by a central adjudication committee whose
members were unaware of the name of the subject, the
enrolling centre, the results of D-dimer, presence or
absence of RVO, thrombophilia and the assigned group.
Statistical analysis
Base-line differences between groups were assessed by the
chi-square test (Yates’ correction) for categorical variables
and t-test or ManneWhitney U test for continuous vari-
ables, as appropriate. Data were analysed on an intention-
to-treat basis. Patients who developed important clinical
conditions different from the study outcomes (such as
ischaemic heart disease, cancer, stroke and superficial vein
thrombosis) and changed their assigned treatment were
regularly followed up and included in the analysis.
Table 3A Hazard ratios for main outcomes.
Hazard ratios (95% CI)
Unadjusted P value Adjusted P value
Abnormal-Dd no VKA
vs. Normal Dd
2.05
(1.16e6.64)
0.014 2.07a
(1.12e3.81)
0.02
Abnormal-Dd þ VKAs
vs. Normal Dd
2.1
(0.7e5.6)
N.S. 2.23b
(0.75e6.6)
N.S.
Abnormal-Dd no VKA
vs. Abnormal-Dd þ VKA
4.2
(1.42e12.3)
0.009 3.76c
(1.26e11.2)
0.018
RVO present
vs. RVO absent
0.81
(0.45e1.46)
N.S. 0.74d
(0.41e1.34)
N.S.
VKA denotes vitamin K antagonist treatment; Dd Z D-dimer; CI Z confidence intervals.
a Adjusted for sex (p Z 0.038), age (N.S.), duration of anticoagulation before enrolment (N.S.), presence or absence of congenital
thrombophilia (N.S.), presence or absence of RVO (N.S.).
b Adjusted for sex (pZ 0.1), age (N.S.), duration of anticoagulation before enrolment (pZ 0.09), presence or absence of congenital
thrombophilia (N.S.), presence or absence of RVO (N.S.).
c Adjusted for sex (N.S.), age (N.S.), duration of anticoagulation before enrolment (N.S.), presence or absence of congenital
thrombophilia (N.S.), presence or absence of RVO (N.S.).
d Adjusted for sex (p Z 0.038), age (N.S.), duration of anticoagulation before enrolment (N.S.), presence or absence of congenital
thrombophilia (N.S.), D-dimer (p Z 0.02).
Risk Factors for Recurrent Venous Thromboembolism 361KaplaneMeier survival curves were plotted to estimate
the cumulative incidence of the primary outcome of symp-
tomatic recurrent VTE combined with major bleeding.
Hazard ratios and their 95% confidence intervals were
calculatedusing theCoxproportional hazardsmodel. Initially
an unadjusted hazard ratio was calculated. Then, a multi-
variate model was constructed, including age, sex, duration
of anticoagulation before enrolment, presence or absence of
RVO and presence/absence of factor V Leiden and/or
prothrombin gene mutation. The data were analysed using
thePrism statistical softwarepackage (Version3.0,GraphPad
Software Incorporated, San Diego, CA, USA) and the SPSS
statistical package (Version11.0, SPSS Inc., Chicago, IL,USA).
Results
Patients and treatment groups
Patientswere enrolled at 30 centres of the Italian Federation
of Anticoagulation Clinics. Fig. 1 shows the study flow-chart.Figure 2 Cumulative incidence of main outcomes according
to D-dimer (Dd denotes D-dimer and VKA vitamin K antagonist
treatment).Among 627 patients, eight were excluded before 1month. Of
the remaining 619 patients, 226 had an abnormal D-dimer
and four were excluded because of the presence of lupus
anticoagulant. The remaining 222 patients were randomised
to either resume or stop VKAs. For this analysis, 42 patients
with isolated PEwere excluded and among the remaining 180
patients with proximal DVT with or without PE, 81 patients
resumed while 99 did not resume VKAs. Among 326 patients
with a normal D-dimer, 76 had an isolated PE and were
excluded from the analysis. This left 310 patients with
proximal DVT with or without PE. Patient base-line charac-
teristics are reported in Table 1. In general, 45% were female
and 54% were aged 65 or older with a mean of 63 years. The
mean duration of VKAs was 12 months (95% confidence
interval (CI): 11e13). Abnormal D-dimer results were signif-
icantlymore frequent in older patients. The presence of RVO
was not affected by the duration of treatment, and its
frequency was similar in subjects with either a normal or
abnormal D-dimer. RVO was more frequently present inFigure 3 Cumulative incidence of main outcomes according
to residual venous obstruction (RVO).
Table 3B Rate of recurrent VTE according to the combination of D-dimer and RVO.
Recurrent VTE & Hazard ratios (95% CI)
n/n total (%) (95% CI) Unadjusted P value Adjusteda P value
Normal-Dd 21/190 7e16 1 e 1 e
RVO absent (11)
Normal-Dd 9/111 4e15 0.70 N.S. 0.68 N.S.
RVO present (8.1) (0.32e1.54) (0.31e1.49)
Abnormal-Dd 11/56 10e32 2.01 N.S. 1.92 N.S.
RVO absent (19.6) (0.97e4.19) (0.90e4.12)
Abnormal-Dd 8/40 9e36 1.76 N.S. 1.58 N.S.
RVO present (20) (0.78e3.98) (0.68e3.69)
a Adjusted for sex (N.S.), age (N.S.), duration of anticoagulation before enrolment (N.S.), presence or absence of congenital
thrombophilia (N.S.).
362 B. Cosmi et al.patients with a previous proximal DVT without PE than in
patients with proximal DVTwith PE.
Total follow-up was 881 patient years with a mean of 1.8
years (range: 1e40 months). A total of 364 patients (68%)
were followed for a minimum of 18 months. One patient
with normal D-dimer (0.2%) was lost to follow-up.
During follow-up, 15 patients changed their assigned
treatment because of the onset of various clinical condi-
tions (11 for superficial vein thrombosis, three for atrial
fibrillation and one for kidney infarction) and their subse-
quent follow-up was included in the analysis, according to
the originally assigned treatment group.
Recurrent venous thromboembolism
Fifty-two recurrences were recorded (23 ipsilateral and 27
contralateral, one case of upper limb DVT and one case of
isolated EP). RVO was present in only 22% (5/23) of patients
with recurrent ipsilateral DVT.
As shown in Table 2(A), primary outcome recurrence
rates were significantly higher in patients with an abnormal
D-dimer randomised not to resume anticoagulation than in
those who resumed VKAs or in those with a normal D-dimer,
with associated hazard ratios which were statistically
significant (Table 3(A)). No difference was observed
between subjects with normal D-dimer and those with an
abnormal D-dimer, who resumed VKAs.0 200 400 600 800
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Figure 4 Cumulative incidence of main outcomes according to t
D-dimer (D-d).As shown in Table 2(B), the rate of recurrent VTE was
similar in subjects with or without RVO who did not resume
anticoagulation with associated non-significant hazard
ratios (Table 3(A)). Figs. 2 and 3 show the cumulative
incidence of primary outcomes according to D-dimer and
RVO, respectively.
When D-dimer and RVO were considered in combination
(excluding patients who resumed VKAs from the analysis) as
shown in Table 3(B) and Fig. 4, the rate of recurrence was
similar in the two subgroups with normal D-dimer, without
or with RVO, and in the two subgroups with abnormal D-
dimer, without or with RVO. However, due to the small size
of samples in these subgroups, the differences were not
statistically significant.
Cardiovascular events, deaths and newly diagnosed
cancers
During follow-up 14 cardiovascular events (2.8%; 1.6%
patient years), eight deaths (1.6%; 0.9% patient years) and
18 newly diagnosed cancers (3.7%; 1.4% patient years)
were recorded. Although the rate of these events was
higher in subjects with abnormal D-dimer than in subjects
with normal D-dimer, the difference was not significant
(data not shown). No effect of RVO, alone or in combi-
nation with D-dimer, was observed on these events (data
not shown).1000 1200
RVO present D-d abnormal
RVO absent D-d abnormal
RVO present D-d normal
RVO absent  D-d normal
he combination of residual venous obstruction (RVO) and
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In a prospective single-centre study,12 we showed that
measuring RVO at the time of VKA withdrawal following
a first episode of idiopathic DVT of the lower limbs was not
predictive of VTE recurrence. Similarly, another single-
centre study reported that both D-dimer and prothrombin
fragment F1þ2, alone and in combination, at 1 month after
VKA withdrawal were associated with a significant risk of
recurrence after a first episode of VTE, while RVO, when
measured at the time of VKA discontinuation, was not
predictive of recurrences.13 In the randomised PROLONG
study,11 we have shown that an abnormal D-dimer at 1
month after anticoagulation withdrawal for a first episode
of VTE is associated with a significant risk of recurrence and
patients benefit from resuming VKAs.
In this post hoc analysis of the PROLONG study, we
evaluated the role of RVO measured at a single time point
in combination with D-dimer in subjects with a first
episode of DVT of the lower limbs enrolled in 30 different
centres. We did not observe a significant effect of RVO at
the time of VKA withdrawal on subsequent recurrences
and we confirmed that an abnormal D-dimer measured 1
month after VKA withdrawal is associated with a signifi-
cantly higher risk of recurrence than normal D-dimer in
patients with proximal DVT of the lower limbs. We also
confirmed that D-dimer is not associated with RVO and in
the presence of abnormal D-dimer, RVO does not
contribute to the risk of recurrence. The rate of recur-
rence was similar in subjects with abnormal D-dimer,
either with or without RVO.
These results are in contrast to those of the AESOPUS14
and DACUS15 studies. These discrepancies could be
explained by several factors, such as different study design
and patient populations and differences in methods and
timing of RVO determination and data analysis.
The AESOPUS14 study randomised patients with both
provoked and unprovoked DVT after 3 months of anti-
coagulation to a fixed duration of anticoagulation (no further
anticoagulation for secondary DVT and an extra 3 month for
idiopathic DVT) or to a flexible duration of ultrasound-guided
anticoagulation (no further anticoagulation in patients with
recanalised veins, continuation of anticoagulation in all
other patients up to a maximum of 9 months for secondary
DVT and 21 months for idiopathic DVT). RVO was measured
according to the method of Prandoni et al.16 Recurrences
were higher in patients allocated to the fixed anticoagulant
duration than in patients randomised to the flexible dura-
tion, for an adjusted hazard ratio of 0.62 (95%CI, 0.39e0.97).
The DACUS15 study was also a randomised trial in which
patients with a first episode of DVT both provoked and
unprovoked, treated with VKAs for 3 months, were
managed according to RVO findings. Those with RVO were
randomised to either stop or continue anticoagulants for 9
additional months, whereas in those without RVO VKAs
were stopped. Recurrent events occurred in 27% of those
who discontinued and 19% of those who continued VKAs. Of
the 78 (30%) patients without RVO, only one (1%) had
a recurrence. The adjusted hazard ratio of patients with
RVO vs. those without was 25 (95% CI, 3.4e183; PZ 0.002).In contrast to the AESOPUS14 and DACUS15 studies, only
patients with unprovoked DVT were enrolled in our study.
As no standardised and universally accepted method of RVO
measurement is available, the reproducibility of this
measurement could be a relevant issue across studies due
to the lack of widely accepted criteria for the definition of
vein recanalisation. While in the AESOPUS and PROLONG
studies the method of Prandoni et al.16 was adopted, in the
DACUS study RVO was measured with CUS of the common
femoral and popliteal veins and defined as a residual
thrombus occupying more than 40% of the vein area
calculated in the absence of compression. The DACUS study
was conducted in only three centres and reproducibility
was assessed only in one centre with adequate inter-
observer and intra-observer variation (kappa Z 0.74; 95%
CI, 0.70e0.86). The AESOPUS study was conducted in nine
centres without any formal assessment of RVO reproduc-
ibility and only a consensus meeting was held before the
beginning of the study to agree on standard procedures. In
the PROLONG study,11 a formal intra- and inter-observer
variation assessment was not conducted, due to the large
number of centres, which in itself may better reflect the
clinical practice of a wide variety of clinicians.
Finally, neither the AESOPUS nor the DACUS studies
evaluated RVO in combination with D-dimer, as we did in
the PROLONG study. So far, our study is the only rando-
mised study evaluating both parameters, albeit with
patients randomised according to D-dimer and not RVO. An
abnormal D-dimer and also the presence of RVO after VKA
withdrawal could be predictors of an increased risk of
cardiovascular events and of occult cancer21 but no effect
of the presence of RVO was observed possibly due to the
small number of events and the small sample size, which
was not calculated for this secondary outcome. After
anticoagulation withdrawal, some patients were started on
anti-platelet agents but it was not possible to accurately
retrieve these data during follow-up.
The results of this study should be evaluated with some
caution. First, the trial was unblinded, and bias could not
be completely ruled out, in spite of a blinded central
adjudication committee and the conduction of a post hoc
analysis. However, event rates in the treated and untreated
patients (both with abnormal and normal D-dimer) are in
the range of those reported in the literature. Second, while
RVO was measured on the day of VKA discontinuation, D-
dimer was tested after 30  10 days. Although RVO, when
present on the day of VKA withdrawal, could be absent
after 30  10 days, it was absent at the subsequent CUS
evaluation (i.e., at 3 months after VKA withdrawal), only in
21/178 (12%) of the patients with RVO on the day of VKA
withdrawal. This seems to indicate that RVO is quite stable
and thus, if present at the time of VKA withdrawal, its
absence is unlikely after 30  10 days. Our patients had
undergone different VKA periods when RVO and D-dimer
were determined; however, the duration of VKA treatment
did not seem to influence either D-dimer or RVO at the time
of VKA withdrawal.
Although RVO could bias the diagnosis of ipsilateral
recurrent DVT, recurrences were ipsilateral in only 23 cases
and RVO was present in five (22%) of subjects with recurrent
ipsilateral DVT, suggesting a lack of association of RVO with
ipsilateral recurrence. Investigators evaluating suspected
364 B. Cosmi et al.recurrences were aware of the characteristics of the index
event but unaware of thrombophilia and D-dimer results.
In conclusion, the PROLONG study confirms that D-dimer
at 1 month after VKA withdrawal is an independent risk
factor for recurrent VTE after a single episode of idiopathic
proximal DVT of the lower limbs and that a single
measurement of RVO at the time of VKA withdrawal neither
predicts late recurrences nor does it increase the risk of
recurrences in the presence of an abnormal D-dimer.
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